Mice dosed with either pAb HCC or anti–PD-L1 monotherapies showed an intermediate profile with a progressive increase of the median clinical score from day 8 to day 35, stabilizing at the end of the protocol with 30% survival. The gene discussed is CD274; the disease is hepatocellular carcinoma.